Figure 4

Combination therapy with niraparib and anti-PD-1 augmented antitumor activity and conferred durable responses in BRCA-deficient tumor models (A) Tumor growth in the BRCA-deficient MDA-MB-436 model in huNOG-EXL mice treated with 200 mg anti-PD-1 (pembrolizumab) on days 0, 4, 9, 13, 18, 22, and 28; 35 mg/kg niraparib daily for 5 days on and 2 days off for 4 weeks; and the combination of these agents. (B) The BRCA1-null ovarian cancer mouse syngeneic model was treated with 30 mg/kg niraparib QD, 10 mg/kg anti-PD-1 (BioXCell RMP1-14) BIW, and the combination of these agents for 21 days (day 9–29). Tumor regrowth was monitored post treatment (days 29–64). (C) The BRCA1-null ovarian cancer mouse syngeneic model was treated with niraparib 50 mg/kg QD, anti-PD-1 10 mg/kg BIW, and the combination of these agents for 21 days (days 9–29). Tumor regrowth was monitored post treatment (days 29–64). (D) Table summarizing the ratio of mice with palpable tumors on day 29 (last treatment day) and the ratio of mice with tumor growth observed during the drug-free, posttreatment observation period (days 30–64). (E) Growth curves for rechallenge with BRCA1-null ovarian cancer cells implanted on day 65 in the tumor-free mice from (D) and age-matched treatment-naïve mice.